er in
diabetes care. The company has the broadest diabetes product
portfolio in the industry, including the most advanced products
within the area of insulin delivery systems. In addition, Novo
Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy.
Novo Nordisk manufactures and markets pharmaceutical products and
services that make a significant difference to patients, the
medical profession and society. With headquarters in Denmark, Novo
Nordisk employs more than 23,600 employees in 79 countries, and
markets its products in 179 countries. Novo Nordisk's B shares are
listed on the stock exchanges in Copenhagen and London. Its ADRs
are listed on the New York Stock Exchange under the symbol 'NVO'.
For more information, visit
http://novonordisk.com.
References:
1. Seino Y, Kaku K, Nishijima K, et al. "Once Daily Dosing of
the long acting GLP-1 analogue Liraglutide Significantly Improves
Glycaemic Control by Reducing both Fasting and Post-Prandial
Glucose Levels In Japanese Subjects With Type 2 Diabetes." Poster
presented (abstract # 0520-P) at the 67th Scientific Sessions of
the American Diabetes Association, Chicago, IL, June 23-26
2007.
2. Vilsboell T, Brock B, Perrild H, et al. 14 weeks of
liraglutide therapy in subjects with T2DM significantly improves
1st phase insulin secretion and maximal beta-cell secretory
capacity. Late-breaking oral presentation (abstract 750195) at:
66th annual meeting of the American Diabetes Association,
Washington, DC, June 9-13, 2006.
3. Vilsboell T, Zdravkovic M, Le-Thi T, et al. Liraglutide
significantly improves glycemic control, and lowers body weight
without risk of either major or minor hypoglycemic episodes in
subjects with type 2 diabetes. Oral presentation (abstract #
115-OR) at: 66th annual meeting of the American Diabetes
Association, Washington, DC, June 9-13, 2006.
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer2.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis3.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial4.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis5.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone6.
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis7.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease8.
NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product9.
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis10.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery11.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery